心脏和脏疾病的协同治疗方法
Deutsches Arzteblatt international
|August 13, 2025
概括
心脏和脏疾病是相关的,并且在德国不断增加. 像SGLT2抑制剂这样的新药类显著降低了患者的发病率和死亡率.
科学领域:
- 心脏病学和脏病学.
- 药物治疗 药物治疗
背景情况:
- 德国心脏和脏疾病发病率上升.
- 慢性病会增加心血管疾病的风险,反之亦然.
- 共同的危险因素包括糖尿病,高血压和炎症.
研究的目的:
- 审查当前对心脏和脏疾病之间的病理生理学联系的理解.
- 总结最近对伴随性心脏和脏疾病的治疗进展.
主要方法:
- 在2025年之前对文献进行叙述性审查.
- 包括德国科学医学会协会 (AWMF) 和欧洲心脏病学会 (ESC) 的指导方针.
- 关于流行病学,诊断和治疗的补充搜索.
主要成果:
- 心脏和脏疾病具有共同的风险因素和病理生理路径.
- ACE 抑制剂,SGLT2 抑制剂,GLP1-RA 和 nsMRA 显著降低了发病率和死亡率.
- 对于结合的终点,观察到1.8%6.7%的绝对风险降低.
结论:
- 心脏和脏疾病是相互关联的,可以通过新型药物治疗来管理.
- 需要进一步研究药物协同作用,多药学和成本有效的护理.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
508
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
508
Heart Failure Drugs: Diuretics
484
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
484
Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Chronic Kidney Disease III: Interprofessional Care
80
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
80
Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
Acute Kidney Injury V: Interprofessional Care
44
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
44


